Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung CancerCasey Liveringhouse, Bradford A. Perez, Stephen A. Rosenberg et al.|International Journal of Radiation Oncology*Biology*Physics|2023Cited by 18
LBA42 Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinomaS. Kim, Andrew S. Brohl, Evan Wuthrick et al.|Annals of Oncology|2022Cited by 0